Everett Harris & Co. CA Invests $2.55 Million in Zimmer Biomet Holdings, Inc. $ZBH

Everett Harris & Co. CA acquired a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 29,647 shares of the medical equipment provider’s stock, valued at approximately $2,552,000.

Several other large investors have also bought and sold shares of ZBH. Main Management ETF Advisors LLC lifted its holdings in Zimmer Biomet by 1.0% during the 4th quarter. Main Management ETF Advisors LLC now owns 10,962 shares of the medical equipment provider’s stock worth $986,000 after buying an additional 112 shares during the period. Citizens National Bank Trust Department increased its stake in shares of Zimmer Biomet by 17.6% in the first quarter. Citizens National Bank Trust Department now owns 941 shares of the medical equipment provider’s stock valued at $85,000 after buying an additional 141 shares during the period. Oppenheimer & Co. Inc. raised its position in shares of Zimmer Biomet by 0.8% during the fourth quarter. Oppenheimer & Co. Inc. now owns 20,363 shares of the medical equipment provider’s stock worth $1,831,000 after acquiring an additional 152 shares during the last quarter. TD Private Client Wealth LLC raised its position in shares of Zimmer Biomet by 15.3% during the fourth quarter. TD Private Client Wealth LLC now owns 1,152 shares of the medical equipment provider’s stock worth $104,000 after acquiring an additional 153 shares during the last quarter. Finally, Leonteq Securities AG lifted its stake in shares of Zimmer Biomet by 5.3% in the first quarter. Leonteq Securities AG now owns 3,062 shares of the medical equipment provider’s stock worth $277,000 after acquiring an additional 153 shares during the period. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Stock Up 1.0%

Shares of Zimmer Biomet stock opened at $100.52 on Friday. Zimmer Biomet Holdings, Inc. has a one year low of $79.12 and a one year high of $108.29. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.69 and a quick ratio of 0.94. The stock’s 50-day moving average is $91.51 and its 200 day moving average is $90.54. The firm has a market cap of $19.17 billion, a price-to-earnings ratio of 24.46, a PEG ratio of 3.17 and a beta of 0.45.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, topping the consensus estimate of $2.01 by $0.06. The business had revenue of $2.18 billion during the quarter, compared to analysts’ expectations of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The firm’s revenue was up 4.8% on a year-over-year basis. During the same quarter last year, the firm posted $2.07 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.53 EPS for the current year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, July 31st. Stockholders of record on Thursday, June 25th were given a dividend of $0.24 per share. The ex-dividend date of this dividend was Thursday, June 25th. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. Zimmer Biomet’s dividend payout ratio (DPR) is 23.36%.

Wall Street Analyst Weigh In

ZBH has been the subject of a number of recent analyst reports. Canaccord Genuity Group increased their target price on shares of Zimmer Biomet from $83.00 to $100.00 and gave the company a “hold” rating in a research report on Monday, August 10th. Wells Fargo & Company dropped their price target on shares of Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 29th. JPMorgan Chase & Co. reduced their price objective on shares of Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 29th. Zacks Research cut shares of Zimmer Biomet from a “hold” rating to a “strong sell” rating in a research report on Monday, July 27th. Finally, Royal Bank Of Canada increased their price objective on shares of Zimmer Biomet from $101.00 to $110.00 and gave the stock an “outperform” rating in a research report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have issued a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, Zimmer Biomet presently has a consensus rating of “Hold” and an average target price of $104.42.

Insider Buying and Selling at Zimmer Biomet

In other news, insider Sang Yi sold 5,000 shares of Zimmer Biomet stock in a transaction on Friday, May 29th. The shares were sold at an average price of $82.64, for a total value of $413,200.00. Following the completion of the sale, the insider owned 27,251 shares in the company, valued at $2,252,022.64. The trade was a 15.50% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 1.28% of the stock is owned by corporate insiders.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.